---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-341293"
form_type: "8-K"
ticker: "SLN"
cik: "0001479615"
company_name: "Silence Therapeutics plc"
filed_at: "2026-08-10T11:57:19+00:00"
generated_at: "2026-08-10T12:00:11.410483+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Silence Therapeutics reports positive Phase 2 SANRECO topline: 88% vs 19% responder rate

## Summary
- Primary endpoint met: 88% clinical responders on divesiran vs 19% placebo (p<0.0001); placebo-adjusted 69%.
- Both dose groups strong: 93.8% response at Q6W, 81.3% at Q12W in 48 phlebotomy-dependent PV patients.
- Phlebotomy rate cut to 0.2 vs 2.1 per patient (p<0.0001); hematocrit control and MPN-SAF TSS improved.
- Well tolerated, no new safety findings; two grade 1 anemia cases. Phase 3 Q12W vs placebo expected 1H'27.

## SEC filing metadata
- accession: 0001193125-26-341293
- form_type: 8-K
- ticker: SLN
- cik: 0001479615
- company_name: Silence Therapeutics plc
- filed_at: 2026-08-10T11:57:19+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479615/000119312526341293/0001193125-26-341293-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479615/000119312526341293/d12947d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-341293
- JSON: https://secwatch.observer/filing/0001193125-26-341293.json
- Plain text: https://secwatch.observer/filing/0001193125-26-341293.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.